Carie Boyd's

Carie Boyd’s runs both a 503B outsourcing facility (office-use batches) and a patient-specific 503A pharmacy — one of the more established dual-status compounders squarely in the consumer wellness space (hormones, aesthetics, weight loss).

Facility & accreditation

The 503B facility (legal entity “Right Value Drug Stores, LLC,” Irving, TX) is on the FDA Registered Outsourcing Facilities list ^[1], and the company also operates a 503A patient-specific pharmacy in Denton, TX ^[2]. It says it ships nationwide with free 2-day shipping ^[2]. On accreditation, a search of ACHC’s PCAB directory did not return a listing for Carie Boyd’s ^[3]; the company doesn’t prominently claim PCAB, so treat accreditation as not independently confirmed.

What they compound

Relevant lines: HRT (hormone pellets, hormone injections, oral bioidentical hormones, topical creams), sexual wellness, dermatology & aesthetics, hair & scalp, anesthetics, and weight management — including sublingual semaglutide (plus naltrexone, bupropion/naltrexone, phentermine/topiramate) ^[2].

Regulatory record

Per the FDA 503B list, the last inspection is logged with an action status of “Regulatory Meeting Held” (2026-01-08) ^[1]. The FDA has issued the Irving 503B facility two warning letters. The first, dated September 20, 2021, followed an inspection from October 28 to November 12, 2019 and cites 503B conditions (labels without NDC numbers or directions for use), CGMP and insanitary conditions ^[4]. The second, dated December 17, 2024, followed an inspection from May 28 to June 21, 2024 and cites 503B labelling conditions, sterile products prepared under insanitary conditions, and unapproved and misbranded drugs, naming testosterone cypionate injections and a ketoconazole cream ^[5]. No close-out letter has been posted for either as of October 20, 2026. Both are in our register of warning letters to compounding pharmacies.

FDA has also posted two Form 483s from later inspections of the same Irving facility (FEI 3010589333). The first was issued July 18, 2025 after an inspection from July 7 to 18, 2025, with five observations: unexplained discrepancies not fully reviewed, missing written in-process controls, contamination-prevention procedures for sterile products not followed, equipment not suited to its use, and incomplete batch records ^[6]. The second was issued September 8, 2026 after an inspection from August 24 to September 8, 2026, with two observations: contamination-prevention procedures for sterile products not followed, and laboratory controls without scientifically sound specifications ^[7]. A Form 483 records an investigator’s observations, and a regulatory meeting is a step FDA uses to discuss corrections; neither is a finding of violation. Dated to our review; status can change.

The read

A well-established, broad-menu dual 503A/503B compounder that fits the consumer HRT/aesthetics/weight-loss audience, with nationwide shipping. Two FDA warning letters to the 503B facility, in 2021 and 2024, neither closed out, and Form 483s after the 2025 and 2026 inspections; accreditation isn’t independently confirmable, which is the main gap versus a PCAB-verified operator like Empower.

References

1. FDA — Registered Outsourcing Facilities (503B) list. (accessed 2026-07-01)
2. Carie Boyd’s Prescription Shop — official site. (accessed 2026-07-01)
3. ACHC / PCAB accredited-organization directory (searched “Carie Boyd”). (accessed 2026-07-01)
4. FDA — Warning letter, Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd’s Prescription Shop, case 610751, September 20, 2021. (accessed 2026-10-21)
5. FDA — Warning letter, Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals, WL 694687, December 17, 2024. (accessed 2026-10-21)
6. FDA — Form 483, Right Value Drug Stores LLC, Irving, TX (issued 2025-07-18). (accessed 2026-10-28)
7. FDA — Form 483, Right Value Drug Stores LLC, Irving, TX, 503B outsourcing facility (issued 2026-09-08). (accessed 2026-10-28)